SIGA Technologies Inc.

I will now turn the call over to your host, Phil Gomez, Chief Executive Officer. Mr. Gomez, you may begin, sir.

Thank you for taking the time to join today's call. Today I'm joined by Dennis Ruby, our Chief Scientific Officer, and Dan Luckshire, our CFO. We are pleased to have this opportunity to provide a business, R&D, and financial update to our shareholders. We'll then be happy to take questions. I'd like to start this call by highlighting our expectations for the second half of 2023 that will be achievable based on the work we have done in the first half of the year. In the second half of 2023, we expect the company to generate approximately $113 million of revenue from deliveries of oral teapots to the U.S. strategic national stockpile and another $30 million to $45 million of revenue from a broad cross-section of domestic and international deliveries. including the deliveries of oral TPOCs to the Department of Defense, IV TPOCs to the U.S. Strategic National Stockpile, and oral TPOCs to international customers. Based on such revenue expectations, we expect to generate full-year 2023 pre-tax operating income of between $90 and $100 million, representing strong growth over the prior year. These financial expectations reflect successful efforts to diversify our revenue base anchored by the aforementioned $113 million order from the U.S. Department of Health and Human Services under our 19-seat contract. The expected deliveries of TPOCs to a broad cross-section of customers is another example of our commitment to consistently meet global demand for TPOCs. Beyond 2023, we will continue to execute on our strategic plan to maximize growth opportunities. I will ask Dennis to provide details on two growth-related initiatives for SIGA, one, the PEP program for oral TPOX, and two, the MPOX randomized control trials and observational trials. Dennis?

Thanks, Phil.